Previous studies on medullary thyroid carcinoma (MTC) have indicated that the MZ-CRC-1 cell line, harboring the p.M918T RET mutation, exhibits greater numbers of CD133+ cells and enhanced sphere-forming ability compared to the TT cell line. This evidence concerns the gene PROM1 and medullary thyroid gland carcinoma.